Substance / Medication

Erythromycin estolate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

129 trials linked to this intervention

129
Total Trials
14
Recruiting
73
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Protective role of tetrahydrocurcumin against erythromycin estolate-induced hepatotoxicity.
Pari L, Murugan P · Pharmacol Res · 2004
PMID: 14998559Observational
Management of cutaneous erythrasma.
Holdiness Mack R · Drugs · 2002
PMID: 12010076Review
Erythromycin Estolate Is a Potent Inhibitor Against HCoV-OC43 by Directly Inactivating the Virus Particle.
Wang Xiaohuan, Chen Yongkang, Shi Huichun et al. · Front Cell Infect Microbiol · 2022
PMID: 35873167OtherFull text (PMC)
Erythromycin Estolate Inhibits Zika Virus Infection by Blocking Viral Entry as a Viral Inactivator.
Wang Xiaohuan, Xia Shuai, Zou Peng et al. · Viruses · 2019
PMID: 31731598PreclinicalFull text (PMC)
Effect of tetrahydrocurcumin on erythromycin estolate-induced lipid peroxidation in rats.
Murugan Pidaran, Pari Leelavinothan · J Basic Clin Physiol Pharmacol · 2005
PMID: 16187483Preclinical
Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis.
Langley Joanne M, Halperin Scott A, Boucher François D et al. · Pediatrics · 2004
PMID: 15231980Trial
Pharmacokinetics of erythromycin estolate and erythromycin phosphate after intragastric administration to healthy foals.
Lakritz J, Wilson W D, Marsh A E et al. · Am J Vet Res · 2000
PMID: 10951982Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Erythromycin estolate (substance)
SNOMED CT
10270000
UMLS CUI
C0014809

Clinical Data

This intervention maps to 19 entities in the Healos knowledge graph.

19
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
129
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.